Project ARTEMIS: A Mechanistic Clinical Trial of Neuroimmune Pathways.

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 59
Healthy Volunteers: f
View:

• 18-59 years old

• Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

• Confirmed HIV diagnosis

• Current receipt of daily oral antiretroviral therapy (ART) medication

• English fluency/literacy

Locations
United States
North Carolina
Wake Forest University School of Medicine
RECRUITING
Winston-salem
Contact Information
Primary
Christina S Meade, PhD
cmeade@wakehealth.edu
336-716-0695
Backup
Sheri L Towe, PhD
stowe@wakehealth.edu
336-716-4331
Time Frame
Start Date: 2025-04-29
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 189
Treatments
Active_comparator: ARTEMIS
Participants in this arm will receive the ARTEMIS intervention immediately following randomization.
Other: Waitlist Control (WLC)
Participants in the WLC arm will be offered the ARTEMIS intervention after the final (6-month) follow-up.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Florida International University
Leads: Wake Forest University Health Sciences

This content was sourced from clinicaltrials.gov